TIDMOCTP
Oxford Cannabinoid Tech.Holdings
17 November 2021
17 November 2021
Oxford Cannabinoid Technologies Holdings plc
New agreement signed with Oxford Stemtech Ltd ("Stemtech")
-- Stemtech to provide state-of-the-art early-stage R&D data
support across all four of OCTP's drug development programmes,
especially Programmes 3 and 4 targeting pain, neurology, and
inflammation
-- Innovative "pain-in-a-dish" model replicates human pain in vitro
Oxford Cannabinoid Technologies Holdings plc ("OCTP" or the
"Company"), the holding company of Oxford Cannabinoid Technologies
Ltd ("OCT", together, the "Group"), a company developing licensed
prescription cannabinoid medicines for approval by regulatory
agencies worldwide and targeting the U$ multi-billion pain market,
is pleased to announce that OCT has signed a new drug development
agreement with Stemtech.
Stemtech is a contract research organisation based in Oxford and
led by Dr Zameel Cader, which generates re-programmed human stem
cells for research and drug discovery. Under the agreement Stemtech
will provide OCT with cutting edge support for its drug development
programmes, starting with Programmes 3 and 4 which are targeting
pain, neurology and inflammation. OCT believes Stemtech's
technology provides an in vitro translational model that will
better predict results in humans. Simply put, Stemtech's model
helps predict which of OCT's compounds (including the library
recently licensed from Canopy Growth Corporation ("Canopy"),
announced on 22 September 2021) have the potential to treat pain in
patients suffering from disorders poorly treated by current
medicines.
Stemtech has developed an innovative "pain-in-a-dish" model
which replicates human pain and which supports both compound
screening and mechanistic studies. By using Stemtech's cutting-edge
multi-electrode array technology (MEA), OCT can measure whether
compounds in its library can reduce the "fire" rate of the neuron
in real time and, thus, identify potential drugs to treat pain.
Stemtech will also screen OCT's drug library (including the library
recently licensed from Canopy) for compounds that can 'switch off'
inflammation at the cellular level.
Together these studies will assist OCT in identifying compounds
with the potential of treating pain and neurological disorders
involving neuro-inflammation and/or neurodegeneration.
OCTP Chief Executive, Dr John Lucas, said of the Oxford Stemtech
partnership: "This exciting technology is delivered by a trusted
partner. It is a natural evolution from the research collaboration
agreement between OCT and Oxford University and is testament to the
scientific excellence of its pain research project, led by
Professor Zameel Cader."
Dr Zameel Cader, Associate Professor of Clinical Neurosciences
at the University of Oxford and Director and Co-Founder of
StemTech, said "We are very glad to be working with OCT to support
the development of multiple programmes. StemTech has developed a
new method that reduces the cost and increases the scale of
reprogramming pluripotent stem cells from healthy volunteers and
patients. This innovative approach allows us to develop in vitro
human disease models for translational research. We are delighted
that OCT has chosen StemTech as their partner of choice in their
efforts to become the global leader in developing cannabinoid-based
prescription medicines in pain and neurological disorders."
Enquiries:
Oxford Cannabinoid Technologies +44 (0)20 3034 2820
Holdings plc john@oxcantech.com
Dr John Lucas (CEO) clarissa@oxcantech.com
Clarissa Sowemimo-Coker (COO)
Walbrook PR Limited +44 (0)20 7933 8780
Paul Vann +44 (0)7768 807631
Nicholas Johnson oxcantech@walbrookpr.com
Harbor Access LLC Richard.Leighton@HarborAccessllc.com
Richard Leighton +1 (475) 455 9403
Jonathan Paterson
About Oxford Cannabinoid Technologies Holdings Plc :
Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the
holding company of Oxford Cannabinoid Technologies Ltd ("OCT"), a
pharmaceutical company developing prescription cannabinoid
medicines for approval by key medicines regulatory agencies
worldwide and targeting the U$ multi-billion pain market (together
the "Group"). Cannabinoids are compounds found in the cannabis
plant that have been shown to have a range of therapeutic effects
on the body, including pain relief. The Group has a clearly defined
path to commercialisation, revenues and growth.
The Group is developing drug candidates through clinical trials
to gain regulatory approval (FDA/MHRA/EMA) that will enable medical
professionals to prescribe them with confidence.
The Group's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key
activities. The Group's lead compound, OCT461201, is a highly
potent and selective CB2 agonist and is being developed by OCT in a
solid oral dosage form. OCT is conducting pre-clinical testing and
development with pre-clinical trials scheduled for 2022. The
Group's product pipeline also uses a balanced drug product strategy
that employs phytocannabinoids, cannabinoid derivatives and other
novel compounds for the treatment of pain.
OCTP operates a partnership model with external academic and
commercial partners, including the University of Oxford.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADZMMMNVLGMZM
(END) Dow Jones Newswires
November 17, 2021 02:00 ET (07:00 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
